Louisiana State University and Agricultural & Mechanical College

South Rampart Pharma, LLC

University of Southern California

The Foundation for the Lsu Health Sciences Center

University of Alcala De Henares

Lsu Medical Center Foundation

Other

Universidad De Alcalà

University of Alcala De Hernares

Board of Supervisors of Lousiana State University and Agricultural and Mechanical College

Nicolas G Bazan

Dennis J Paul

Julio Alvarez-Builla

Nicos A Petasis

Carlos Sunkel

Hernan Bazan

Julio Alvarez-Builla Gomez

Carolina Burgos Garcia

Haydee E P Bazan

Mark A DeCoster

Haydee E Bazan

Jiu-Cheng He

Carolina Burgos

Anthony Vaccarino

Alberto E Musto

Provided are compositions that include a platelet-activating factor antagonist, pharmaceutical compositions including the platelet-activating factor antagonist, methods of treating a modulating the proliferation of a glioma or a pathological condition resulting from patient having a glioma.

Compositions and methods for the treatment of seizure caused by brain tumor

This disclosure provides compounds, pharmaceutical compositions, and methods of use for the prevention and treatment of inflammatory diseases or degenerative diseases including neurodegenerative diseases. Embodiments of the present disclosure provide compounds related to very long chain polyunsaturated fatty acids, pharmaceutical compositions containing the provided compounds, and methods of treating a subject with a condition or disease using provided compounds or pharmaceutical compositions.

Compounds, compositions, and methods for the treatment of inflammatory, degenerative, and neurodegenerative diseases

Provided are compounds, pharmaceutical compositions, cosmetic and dermatological compositions or nutritional supplement compositions, comprising omega-3 very-long-chain polyunsaturated fatty acids (n-3 VLC-PUFAs) and/or their endogenous hydroxylated derivatives thereof, known as elovanoids. This disclosure provides methods for neuroprotection, organ and tissue protection or restoration, prevention or slowing down of aging-related diseases and conditions, and sustainment of function during the aging process.

Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use

This invention is directed to compositions, methods and kits that can be used for the treatment or amelioration of pain and fever.

Compositions and methods for ameliorating pain and reducing fever

This invention is directed to compositions, methods and kits that can be used for the treatment or amelioration of pain.

Compositions and methods for ameliorating pain

Lipoxin A4 and its analogs have been discovered to promote the cell proliferation of cornea endothelial cells, and thus promote the proper functioning of the labile tissue layer of cornea endothelial cells. These lipoxin compounds can be administered alone or in combination with other known compounds as a solution that can be topically administered to decrease the swelling of the cornea or maintain the clarity of the cornea. Lipoxin A4 or its analogs can also be combined with other known nutritive compounds to form a solution for storage of a cornea prior to transplantation.

Lipoxin A4 protection for cornea endothelial cells

The invention is an electromagnetic probe used in conjunction with a ferrofluid containng M particles. The electromagnetic probe is used to steer M-particles to a desired location, or use the M particles for mixing the ferrofluid. The probe can be used in conjunction with a microscope, a micromanipulator, a catheter or endoscope.

Electromagnetic probe device

The present invention relates to pharmaceutical combinations of opioid and non-opioid analgesics in an intimate admixture with caffeine and an analgesic from a series of N-acylated 4-hydroxyphenylamine derivatives, linked via an alkylene bridge to the nitrogen atom of a 1,2-benzisothiazol-3(2H)-one 1,1-dioxide group and methods for their use to alleviate pain in mammals. The analgesic combinations exhibit enhanced analgesic potency and are free from antipyretic activity, do not suppress blood coagulation, and have little hepatotoxic effect.

Synergistic combinations including N-acylated 4-Hydroxyphenylamine derivatives and caffeine

The present invention relates to pharmaceutical combinations of opioid and non-opioid analgesics in an intimate admixture with an analgesic from a series of N-acylated 4-hydroxyphenylamine derivatives, linked via an alkylene bridge to the nitrogen atom of a 1,2-benzisothiazol-3(2H)-one 1,1-dioxide group and methods for their use to alleviate pain in mammals. The analgesic combinations exhibit enhanced analgesic potency, do not suppress blood coagulation, and have little hepatotoxic effect.

Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives

New analgesic compounds, which are prepared by the hydrolysis of N-acylated 4-hydroxyphenylamine derivatives, their synthesis and pharmaceutical compositions containing them are disclosed. These compounds surprisingly possess high analgesic activity with little hepatotoxic effect, making them more useful than conventional non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of chronic pain.

Analgesic compounds, their synthesis and pharmaceutical compositions containing them

The present invention relates to a series of new N-acylated 4-hydroxyphenylamine derivatives, linked via an alkylene bridge to the nitrogen atom of a 1,2-benzisothiazol-3(2H)-one 1,1-dioxide group of formula I: ##STR1## in which n is a number from 1 to 5, and to processes for preparing these derivatives and to pharmaceutical compositions containing said derivatives; these compounds possess high analgesic activity free from antipyretic activity, and they display little hepatotoxic effect.

Process for preparing N-acylated 4-hydroxypenylamine derivatives with

The present invention relates to a series of new N-acylated 4-hydroxyphenylamine derivatives, linked via an alkylene bridge to the nitrogen atom of a 1,2-benzisothiazol-3(2H)-one 1,1-dioxide group, of formula I: ##STR1## in which n is a number from 1 to 5, and to processes for preparing these derivatives and to pharmaceutical compositions containing said derivatives; these compounds possess high analgesic activity free from antipyretic activity, and they display little hepatotoxic effect.

Growing community of inventors

New Orleans, LA, United States of America

Nicolas G Bazan